Welcome to our dedicated page for Keros Therapeutics news (Ticker: KROS), a resource for investors and traders seeking the latest updates and insights on Keros Therapeutics stock.
Keros Therapeutics, Inc. (Nasdaq: KROS) is a clinical-stage biopharmaceutical company whose news flow centers on its TGF-ß pathway–focused pipeline, corporate strategy and capital allocation decisions. The company’s disclosures describe a focus on developing protein therapeutics for disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins, with particular emphasis on neuromuscular and hematologic conditions.
News about Keros frequently highlights clinical development milestones for its lead product candidate, KER-065, which is being developed for neuromuscular diseases with an initial focus on Duchenne muscular dystrophy. Recent updates have included Phase 1 clinical data in healthy volunteers, additional analyses of bone and muscle-related endpoints, and U.S. Food and Drug Administration Orphan Drug designation for KER-065 in DMD. Investors following KROS news can expect coverage of trial design, safety and pharmacodynamic findings, and plans for subsequent clinical phases.
Another recurring theme in Keros news is progress related to elritercept, the company’s most advanced product candidate for cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and myelofibrosis. The company has reported developments under its global license agreement with Takeda Pharmaceuticals U.S.A., Inc., including Takeda’s plans to advance elritercept into a Phase 3 clinical trial in first-line myelodysplastic syndromes.
Keros’ news flow also includes corporate and financial updates. These have covered a strategic realignment to prioritize KER-065, discontinuation of internal development of cibotercept (KER-012), leadership and board changes, and a substantial capital return program involving stock repurchase agreements and a cash tender offer for a significant portion of its outstanding common stock. Earnings releases and Form 8-K filings provide additional context on financial results, cash position and the execution of the capital return plan.
For investors and observers, the KROS news page offers a consolidated view of clinical trial announcements, regulatory designations, partnership developments, governance changes and capital allocation actions that shape the company’s trajectory. Regular review of these updates can help track how Keros advances its TGF-ß–focused pipeline and manages its resources over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Keros Therapeutics, a clinical-stage biopharmaceutical company (Nasdaq: KROS), announced the appointment of Alpna Seth, Ph.D., to its Board of Directors, effective May 1, 2023. Dr. Seth brings extensive experience in drug development and global operations, having previously served as CEO of Nura Bio and COO of Vir Biotechnology. Her expertise includes leadership roles at Biogen, where she was instrumental in drug commercialization and development. Keros focuses on innovative treatments for hematological, pulmonary, and cardiovascular disorders, with notable candidates such as KER-050 for cytopenias and KER-012 for pulmonary arterial hypertension. The addition of Dr. Seth is seen as a strategic move to enhance the company's capabilities at a crucial time.
Keros Therapeutics (KROS) reported its fourth quarter and full year 2022 financial results, revealing a net loss of $29.7 million for Q4 and $104.7 million for the entire year, significantly up from $6.9 million and $58.7 million in 2021, respectively. The increase is attributed to heightened research and development costs, particularly for the Phase 2 trials of KER-050 targeting myelodysplastic syndromes and myelofibrosis. Keros maintained a strong cash position of $279.0 million as of December 31, 2022, sufficient to fund operations into Q3 2025. The company outlined several key milestones for 2023, including expanded trials for KER-050 and KER-047.
Keros Therapeutics, Inc. (Nasdaq: KROS), a biopharmaceutical company, announced that its President and CEO Jasbir S. Seehra, Ph.D., will participate in a fireside chat at Cowen’s 43rd Annual Health Care Conference on March 8, 2023, at 11:10 a.m. Eastern time. The event will provide insights into Keros’ innovative treatments for hematological, pulmonary, and cardiovascular disorders. A live audio webcast can be accessed here, with an archived replay available on Keros’ website for up to 90 days post-event.